Reactive A1 Astrocyte-Targeted Nucleic Acid Nanoantiepileptic Drug Downregulating Adenosine Kinase to Rescue Endogenous Antiepileptic Pathway
ACS Applied Materials & Interfaces · 2023
DOI: 10.1021/acsami.3c03455 ↗Kurz gefasst
Fachartikel in der Zeitschrift ACS Applied Materials & Interfaces, 2023. Verfasst von Jianwei Zhu und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu 611731, China. Hauptthemen laut MEDLINE: Nucleic Acids, Epilepsy. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 47 Literaturangaben. Gefördert von: West China School of Stomatology, Sichuan University, National Key Research and Development Program of China, China Postdoctoral Science Foundation.
Abstract (Originalsprache)
Resistance to traditional antiepileptic drugs is a major challenge in chronic epilepsy treatment. MicroRNA-based gene therapy is a promising alternative but has demonstrated limited efficacy due to poor blood-brain barrier permeability, cellular uptake, and targeting efficiency. Adenosine is an endogenous antiseizure agent deficient in the epileptic brain due to elevated adenosine kinase (ADK) activity in reactive A1 astrocytes. We designed a nucleic acid nanoantiepileptic drug (tFNA-ADKASO@AS1) based on a tetrahedral framework nucleic acid (tFNA), carrying an antisense oligonucleotide targeting ADK (ADKASO) and A1 astrocyte-targeted peptide (AS1). This tFNA-ADKASO@AS1 construct effectively reduced brain ADK, increased brain adenosine, mitigated aberrant mossy fiber sprouting, and reduced the recurrent spontaneous epileptic spike frequency in a mouse model of chronic temporal lobe epilepsy. Further, the treatment did not induce any neurotoxicity or major organ damage. This work provides proof-of-concept for a novel antiepileptic drug delivery strategy and for endogenous adenosine as a promising target for gene-based modulation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Neurosurgery, Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu 611731, China.
- Department of Neurosurgery, West China Hospital of Sichuan University, Chengdu 610041, P. R. China.
- State Key Laboratory of Oral Diseases National Clinical Research Center for Oral Diseases, West China Hospital of Stomatology, Sichuan University, Chengdu, 610041, P. R. China.
- Sichuan Provincial Engineering Research Center of Oral Biomaterials, Chengdu, Sichuan 610041, China.
ORCID-Profile: Yunfeng Lin
Förderung
- West China School of Stomatology, Sichuan University
- National Key Research and Development Program of China
- China Postdoctoral Science Foundation
- Sichuan Province Youth Science and Technology Innovation Team
- National Natural Science Foundation of China
- Sichuan Province Science and Technology Support Program
Zitieren
APA
Zhu, J., Qiu, W., Wei, F., Wang, Y., Wang, Q., Ma, W., Xiong, H., Cui, Y., Li, X., Xu, R., & Lin, Y. (2023). Reactive A1 Astrocyte-Targeted Nucleic Acid Nanoantiepileptic Drug Downregulating Adenosine Kinase to Rescue Endogenous Antiepileptic Pathway. ACS Applied Materials & Interfaces. https://doi.org/10.1021/acsami.3c03455
Vancouver
Zhu J, Qiu W, Wei F, Wang Y, Wang Q, Ma W, et al. Reactive A1 Astrocyte-Targeted Nucleic Acid Nanoantiepileptic Drug Downregulating Adenosine Kinase to Rescue Endogenous Antiepileptic Pathway. ACS Applied Materials & Interfaces. 2023. doi:10.1021/acsami.3c03455
BibTeX
@article{Zhu2023,
author = {Zhu, Jianwei and Qiu, Wenqiao and Wei, Fan and Wang, Yangyang and Wang, Qiguang and Ma, Wenjuan and Xiong, Huan and Cui, Yan and Li, Xinda and Xu, Ruxiang and Lin, Yunfeng},
title = {Reactive A1 Astrocyte-Targeted Nucleic Acid Nanoantiepileptic Drug Downregulating Adenosine Kinase to Rescue Endogenous Antiepileptic Pathway},
journal = {ACS Applied Materials & Interfaces},
year = {2023},
doi = {10.1021/acsami.3c03455}
}
EUVIMED